Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro

Chinese Medical Journal

Volumn 121, Issue 7, 2008, Pages 602-607

  Hao, Ji Qing ^a   Li, Qi ^a   Xu, Shu Ping ^a   Shen, Yu Xian ^a   Sun, Gen Yun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Cyclooxygenase 2 inhibitors; Docetaxol; Lumiracoxib; Lung cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACRIDINE ORANGE; DOCETAXEL; LUMIRACOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DRUG DERIVATIVE; TAXOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRUCTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; CELL CYCLE; DRUG EFFECT; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DICLOFENAC; HUMANS; LUNG NEOPLASMS; TAXOIDS;

EID: 46449085634     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200804010-00006     Document Type: Article

References (25)

1. O'Byrne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, et al. Towards a biological staging model for operable nonsmall cell lung cancer. Lung Cancer 2001; 34: S83-S89.
2. Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, et al. Targeting cyclooxygenase-2 in recurrent nonsmall cell lung cancer: a phase II trial of celecoxib and docetaxol. Clin Cancer Res 2005; 11: 6634-6640.
3. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in nonsmall cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005; 65: 6275-6281.
4. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 1001-1005.
5. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
6. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94: 3336-3340.
7. Kozaki K, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, Takahashi T. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res 2000; 60: 2535-2540.
8. Kozaki K, Koshikawa K, Tatematsu Y, Miyaishi O, Saito H, Hida T, et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 2001; 20: 4228-4234.
9. Rordorf CM, Choi L, Marshall P, Mangold JB. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2005; 44: 1247-1266.
10. Lyseng-Williamson KA, Curran MP. Lumiracoxib. Drugs 2004; 64: 2237-2246.
11. Li FF, Wang DC, Jiang J. Study on the synthesis of Lumiracoxib. Chem Ind Times (Chin) 2006; 20: 46-50.
12. Cao SS, Zhen YS. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B. Cancer Chemother Pharmacol 1989; 24: 181-186.
13. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-2645.
14. Ermert L, Dierkes C, Ermert M. Immunohistochemical expression of cyclooxygenase isoenzymes and downstream enzymes in human lung tumors. Clin Cancer Res 2003; 9: 1604-1610.
15. Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, et al. Nitric oxide synthase, cyclooxygenase-2, and vascular endothelial growth factor in the angiogenesis of nonsmall cell lung carcinoma. Clin Cancer Res 2000; 6: 4739-4744.
16. Kim HS, Youm HR, Lee JS, Min KW, Chung JH, Park CS. Correlation between cyclooxygenase-2 and tumor angiogenesis in nonsmall cell lung cancer. Lung Cancer 2003; 42: 163-170.
17. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
18. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311.
19. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004; 43: 467-478.
20. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364: 675-684.
21. Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber J, et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 51: 549-557.
22. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes:evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003; 278: 37637-37647.
23. Berchem GJ, Bosseler M, Mine N, Avalosse B. Nanomolar range docetaxol sensitizes MCF-7 cells to chemotherapy induce apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 1999; 19: 535-540.
24. Moos PJ, Muskardin DT, Fitzpatrick FA. Effect of taxol and taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J Immunol 1999; 162: 467-473.
25. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperaiive paclitaxel and carboplatin in early-stage nonsmall-cell lung cancer. J Clin Oncol 2003; 21: 2645-2650.